Compare Dollar Tree, Inc. (DLTR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs BIO-TECHNE Corp — how do they compare? Dollar Tree, Inc. trades at $118.62 (market cap $21.82B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Dollar Tree, Inc. is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Dollar Tree, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar Tree, Inc. for 58 Days and BIO-TECHNE Corp for 63 Days on average.
| DLTR | TECH | |
|---|---|---|
Market Cap | $21.82B | $11.37B |
Volume | 1,613,659 | 3,153,511 |
Sector | Consumer Staples | Health |
52-Week High | $141.21 | $72.61 |
52-Week Low | $86.80 | $43.31 |
Typical Hold Time | 58 Days | 63 Days |
Enterprise Value | $28.43B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $116.3, up slightly by 0.09% on the day, with a bullish technical signal and strong analyst support. The stock shows robust earnings beats in recent quarters, with Q2 2026 EPS of $2.70 significantly exceeding the $1.15 estimate. Revenue for 2025 was $17.58 billion, though net income was negative due to a large tax expense, while 2026 projections indicate a return to profitability. Strategic initiatives like store expansions and a multi-price strategy are driving growth, supported by positive institutional buying activity.
The outlook for DLTR is positive, with a consensus price target of $139.33 offering ~20% upside. Key opportunities include continued earnings momentum and market share gains, but risks involve margin pressures from tariffs and rising costs. Investors should weigh the strong ROE of 45.87% against volatility in net income and competitive discount retail dynamics.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
